Add-on combination therapy w/ metformin, metformin & a sulfonylurea, metformin & pioglitazone in adult patients w/ type 2 DM to improve glycemic control when the existing therapy, along w/ diet & exercise, does not provide adequate glycemic control. For study results w/ respect to combination of therapies, effects on glycaemic control & CV events. Symptomatic chronic heart failure w/ reduced ejection fraction.
Recommended starting dose: 10 mg once daily. In patients tolerating empagliflozin 10 mg once daily who have an eGFR ≥60 mL/min/1.73 m2 & requiring additional glycemic control, the dose can be increased to 25 mg once daily. Max daily dose: 25 mg. Heart failure 10 mg once daily.
Not to be used in patients w/ type 1 diabetes or treatment of diabetic ketoacidosis. Patients on a very low carbohydrate diet, acute illness, pancreatic disorders suggesting insulin deficiency, insulin dose reduction, alcohol abuse, severe dehydration, history of ketoacidosis. Vol-depletion risk in patients w/ known CV disease, on antihypertensive therapy w/ history if hypotension or patients ≥75 yr; conditions that may lead to fluid loss eg, GI illness. Cardiac failure (NYHA class I-IV), complicated UTI. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. False +ve result in glucose urine test. Not recommended in patients w/ eGFR <20
mL/min/1.73 m2. Not to be used in patients w/ ESRD, on dialysis. Assessment of renal function is recommended. Hepatic injury. May effect ability to drive & use machines. Pregnancy & lactation. Childn <18 yr. Elderly ≥85 yr.
Sign Out
